In-vitro bactericidal activity of cefpirome in combination with vancomycin against Staphylococcus aureus and coagulase-negative staphylococci.
In an in-vitro study of the bactericidal activity of cefpirome in combination with vancomycin against 11 clinical isolates of staphylococci, cefpirome at a concentration of 0.25 times the MIC acted synergistically with vancomycin (at a concentration of 0.5, 1 or 2 times the MIC) against Staphylococcus aureus and coagulase-negative staphylococci susceptible or resistant to methicillin. Moreover, increasing the cefpirome concentration to 0.5 or 1 times the MIC combined with vancomycin at the same concentration (0.5 or 1 times the MIC) improved the bacterial killing rate; a bactericidal effect was obtained in 9 or 24 h instead of in 24 or 48 h, respectively.
Raymond
J
J
Service Microbiologie, Hôpital Saint Vincent de Paul, Paris, France.
Vedel
G
G
Bergeret
M
M
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002511:Cephalosporins / Q000494:pharmacology*; D003030:Coagulase / Q000378:metabolism*; D004359:Drug Therapy, Combination / Q000494:pharmacology*; D007700:Kinetics; D016106:Methicillin Resistance; D008826:Microbial Sensitivity Tests; D013210:Staphylococcus / Q000187:drug effects* / Q000201:enzymology*; D013211:Staphylococcus aureus / Q000187:drug effects*; D014640:Vancomycin / Q000494:pharmacology*; D000097572:Cefpirome
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D003030:Coagulase; D014640:Vancomycin; D000097572:Cefpirome